The Role of Levosimendan in Patients with Decreased Left Ventricular Function Undergoing Cardiac Surgery
Open Access
- 28 June 2016
- journal article
- review article
- Published by Scientific Foundation SPIROSKI in Open Access Macedonian Journal of Medical Sciences
- Vol. 4 (3), 510-516
- https://doi.org/10.3889/oamjms.2016.071
Abstract
The postoperative low cardiac output is one of the most important complications following cardiac surgery and is associated with increased morbidity and mortality. The condition requires inotropic support to achieve adequate hemodynamic status and tissue perfusion. While catecholamines are utilised as a standard therapy in cardiac surgery, their use is limited due to increased oxygen consumption. Levosimendan is calcium sensitising inodilatator expressing positive inotropic effect by binding with cardiac troponin C without increasing oxygen demand. Furthermore, the drug opens potassium ATP (KATP) channels in cardiac mitochondria and in the vascular muscle cells, showing cardioprotective and vasodilator properties, respectively. In the past decade, levosimendan demonstrated promising results in treating patients with reduced left ventricular function when administered in peri- or post- operative settings. In addition, pre-operative use of levosimendan in patients with severely reduced left ventricular ejection fraction may reduce the requirements for postoperative inotropic support, mechanical support, duration of intensive care unit stay as well as hospital stay and a decrease in post-operative mortality. However, larger studies are needed to clarify clinical advantages of levosimendan versus conventional inotropes.Keywords
This publication has 50 references indexed in Scilit:
- The role of levosimendan in acute heart failure complicating acute coronary syndrome: A review and expert consensus opinionInternational Journal of Cardiology, 2016
- Levosimendan for Prevention of Acute Kidney Injury After Cardiac Surgery: A Meta-analysis of Randomized Controlled TrialsAmerican Journal of Kidney Diseases, 2016
- Perioperative Levosimendan Therapy Is Associated With a Lower Incidence of Acute Kidney Injury After Cardiac SurgeryJournal of Cardiovascular Pharmacology, 2014
- Levosimendan: current data, clinical use and future development2013
- Levosimendan reduces heart failure after cardiac surgery: A prospective, randomized, placebo-controlled trial*Critical Care Medicine, 2011
- Lowered B-Type Natriuretic Peptide in Response to Levosimendan or Dobutamine Treatment Is Associated With Improved Survival in Patients With Severe Acutely Decompensated Heart FailureJournal of the American College of Cardiology, 2009
- Levosimendan vs. dobutamine: outcomes for acute heart failure patients on β‐blockers in SURVIVE†European Journal of Heart Failure, 2009
- A review of levosimendan in the treatment of heart failureVascular Health and Risk Management, 2006
- Levosimendan in Cardiac Surgery: Current Best Available EvidenceThe Annals of Thoracic Surgery, 2006
- Levosimendan, a New Calcium‐Sensitizing Inotrope for Heart FailurePharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2004